Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc, announced new data shared at the recent American Society for Dermatologic Surgery (ASDS) Annual Meeting, which took place November 13–16, 2025, in Chicago, Illinois.
Pivotal FDA Study Comparison of Two Hyaluronic Acid Fillers for Midface Augmentation and Associated Improvement in Nasolabial Folds Appearance led to Obagi Hyaluronic Acid Featured as a Top 10 Abstract Presented by Dr. Sue Ellen Cox:
“As an investigator in this pivotal study, I was pleased that the data was recognized as one of the top 10 abstracts and selected for an oral presentation,” commented Dr. Sue Ellen Cox. “The data highlights the compelling results of the Obagi® saypha® ChIQ™ pivotal study and shows the potential of the product to provide high-level satisfaction for patients seeking long-lasting, natural-looking results.”
This pivotal, randomized, multicenter trial compared the effectiveness and safety of two hyaluronic acid fillers for midface volume restoration and nasolabial fold improvement. The study demonstrated non-inferiority of Obagi® saypha® ChIQ™ ** compared to Juvéderm Voluma® XC, with high patient satisfaction and robust safety across diverse skin types.
Additional Abstracts:
Obagi Scalp Serum Interim 3 Month Results
Interim data from the ongoing study of Obagi Nu-Cil® BioStim™ Scalp Serum highlights improvements in scalp health and hair appearance at three months.
A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies
This research introduces a novel framework for evaluating HA fillers and showcases category-leading capabilities of the Obagi line of injectables.
“Obagi Medical’s commitment to advancing dermatologic science and driving innovation is reflected in the data shared across our skincare and injectable portfolio at the recent ASDS meeting,” said Drew Fine, U.S. General Manager, Professional Channel. “New products with proven quality, a well-established safety profile, and high patient satisfaction are critical to expanding the aesthetic injectable market. The selection of the Obagi® saypha® ChIQ™ abstract as one of the top 10 for oral presentation highlights the powerful data supporting the new Obagi injectable.”
Nu-Cil® BioStim™ Scalp Serum expands on Obagi’s 35 years of skin health expertise and leadership in medical-grade innovation by applying its skin-first philosophy to the scalp through the BioStim™ Complex. The BioStim™ Complex utilizes proprietary technology powered by a synergistic blend of clinically proven actives, including biotin, amino acids, and peptides—alongside 18 essential nutrients, B vitamins, and phytoactives. These actives work to promote scalp health, fortify hair follicles, and strengthen strands from the root.
Obagi® saypha® ChIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology that creates a stable 3D HA matrix designed to provide natural-looking results with category-leading capabilities, including high HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile. Obagi® saypha® ChIQ™ is currently under review for FDA approval. Obagi Medical’s Obagi® saypha® MagIQ™ was recently FDA approved.
